Nutrition in Gastroenteropancreatic Neuroendocrine Tumor

Gastro-enteropancreatic neuroendocrine tumor

Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of PT217 in Patients With Advanced Refractory Cancers Expressing DLL3 TQ (Thymoquione) Formula With Nivolumab and Ipilimumab in Gastroenteropancreatic Neuroendocrine Carcinomas Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3) Neuroendocrine Tumors – Patient Reported Outcomes A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET Nutrition in Gastroenteropancreatic Neuroendocrine Tumor Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases The Lyon Real World Evidence in Metastatic NeuroEndocrine Tumours 177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET [68 Ga]-DOTANOC PET/CT in GEP-NETs Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3 Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine Tumours TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors